Nagy Á et al.: KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer, International Journal of Cancer (2017)

Menyhárt O et al: Guidelines for the selection of functional assays to evaluate the hallmarks of cancer, BBA Reviews on Cancer (2016)

Sztupinszki Zs et al.: Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models, Scientific Reports (2016)

Lánczky A et al. : miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2,178 breast cancer patients, Breast Cancer Res Treat (2016)

Munkácsy Gy, Sztupinszki Zs et al: Validation of RNAi silencing efficiency using gene array data shows 18.5% failure rate across 429 independent experiments, Molecular Therapy — Nucleic Acids (2016)

Szász MA et al: Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget (2016)

Szász AM et al: Cancer heterogeneity determined by functional proteomics. Seminars in Cell & Developmental Biology (2016)

Győrffy B et al: Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes. International Journal of Cancer (2016)

Pongor L et al: A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients, Genome Medicine (2015)

Győrffy B et al: Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Research (2015)